TransMedics Group closed Tuesday at $80.75, up 5.8% on the week — but that headline gain masks a more complicated story. Analysts filed a wave of target-price cuts within hours of the company reporting earnings on August 4, even as the stock held its ground.
The Street's direction of travel is decisively lower on price targets, though not on conviction. Piper Sandler trimmed its target from $120 to $100 yesterday while holding Overweight, and Needham cut from $142 to $106 just days earlier, keeping its Buy rating intact. UBS initiated coverage last week at Neutral with an $80 target — essentially flat to the current price, a pointed contrast with the bulls. The consensus remains Buy with a mean target of $98.80, implying roughly 22% upside from current levels, but the direction of estimate revisions tells a harder story. EPS momentum ranks in the bottom decile of the universe over both 30- and 90-day windows, and the 12-month forward EPS growth score ranks near the bottom fifth. Valuation has expanded: the P/E has climbed about 4.9 points over the past month to 31.5x, while EV/EBITDA holds around 13.8x. Bulls point to the Organ Care System's potential to reshape organ transplantation outcomes and the prospect of stronger reimbursement; bears cite rising operating costs, CMS pressure on the OPO market, and execution risk around the aviation logistics buildout.
Short interest is substantial and worth watching closely. Nearly 23.3% of the free float is sold short — one of the heavier loads in the health care equipment sector — and it has crept up roughly 1.8% over the past week to about 7.96 million shares. The ORTEX short score has been nudging higher too, reaching 73.6 on August 4, its highest reading of the tracked period. What makes the short positioning less combustible than it might appear is the borrow market. Cost to borrow is running at just 0.44%, barely changed month-on-month, and availability has dropped sharply this week — from around 85% a week ago to 73% now, hitting the tightest level of the year. That tightening is worth tracking: it has moved from comfortably loose territory (above 100% as recently as mid-July) to genuinely snug in the space of three weeks. The options market adds a mild defensive tinge. The put/call ratio edged up to 0.68 on August 4, about 1.3 standard deviations above its 20-day average of 0.63, though it remains well below the 52-week high of 0.78 — more cautious than alarmed.
The earnings reaction data shows one comparable print: a July 31 result that drove a +7.1% one-day move. The August 4 report landed with the stock essentially flat on the day before Tuesday's minor pullback, suggesting the market absorbed the results without a strong directional verdict. BlackRock holds 15.3% of shares and added modestly in the most recent reported period. FMR (Fidelity) holds a further 14.7%, having also added to its position. The founder and CEO Waleed Hassanein retains a 1.6% stake, essentially unchanged.
The next focal point is whether availability continues to tighten as short sellers maintain elevated positions into a period of downward analyst revisions — and how the stock navigates that pressure against a consensus that still sees it trading well below fair value.
See the live data behind this article on ORTEX.
Open TMDX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
